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Chronic ITP: Analysis of various factors at presentation which predict failure to
first line treatment and their response to second line therapy
Naveen Naz Syed, Salman Naseem Adil, Raihan Sajid, Mohammad Usman, Bushra Moiz, Ghulam Nabi Kakepoto,
Mohammad Khurshid
Department of Pathology and Microbiology, Aga Khan University Hospital, Karachi
Abstract
Objective: To observe the significance of various factors in chronic idiopathic thrombocytopenic purpura (ITP)
which predict the response of first line (corticosteroids) and second line therapy (splenectomy) and to evaluate
their response to second line therapy.
Methods: This was a descriptive, prospective study conducted from August 2004 till January 2006. Patients of
all age groups and both genders with diagnosis of chronic ITP were included. Treatment protocol and criteria for
response assessment was explained.
Results: During 17 months period, 86 patients with chronic ITP were analyzed. Non-responders to first line ther-
apy were 74 patients who ultimately required splenectomy. Complete response (CR) was had in 37 (50.7%)
patients, 10 (13.7%) and 27 (36.5%) had partial response (PR) and no response (NR) respectively. Analysis of
variables like younger age, sex and low platelet count at presentation failed to show any significant influence on
response to first line treatment. However response to splenectomy was found to be higher in patients who had
initial complete or partial response with steroids and later relapsed and the platelet count was more than
300x109/L on day 14 of surgery. 
Conclusion: Splenectomy remains the most effective treatment of chronic ITP.  No significant factor was iden-
tified which predicted initial response to first line treatment. However patients who initially responded to steroids
and had platelet counts above 300 X109/L about a fortnight after splenectomy showed promising results post-
operatively (p=0.003 and p=0.001) (JPMA 57:126;2007).
Introduction
Idiopathic thrombocytopenic purpura (ITP) is an acquired
autoimmune disease characterized by platelet destruction
caused by an anti-platelet autoantibody. The autoantibody-
platelet complex is captured by the reticuloendothelial sys-
tem, which is particularly prominent in the spleen.1,2
Once the decision to treat patients with ITP has been
made, corticosteroids are the standard initial treatment.3-6
Patients who fail to respond to steroids after six months are
considered to have chronic ITP1. 
Splenectomy has been the single best option for
those who fail to respond to first line treatment (corticos-
teroids), or relapse afterwards; it results in complete or par-
tial remission requiring no further therapy in two-thirds of
patients.2,6,7
Splenectomy is often cited as first line therapy but
seldom used and considered as second line therapy.6,8 The
timing of the procedure depends on disease severity,
responsiveness and side effects of medical treatment and
patients and doctor preferences.5
Furthermore, pre and/or post-operative parameters
that are able to predict the response to splenectomy are not
fully recognized.1,9-11 Multiple patients and disease charac-
teristics have been reported, but the findings are inconsis-
tent. The principal site of platelet sequestration determined
by Indium-labelled autologus platelet scanning appears to
be the most sensitive indicator9 to date; however few stud-
ies have not shown a  significant association.12
Similarly little is known about the factors which pre-
dict the response to steroids. No comparable data is avail-
able in this regard on regional basis.
To contribute to these issues; we performed an
analysis on patients with chronic ITP to determine the over-
all outcome of splenectomy.  We also evaluated the signifi-
cance of various factors which predict the initial response to
steroids and splenectomy.
Patients and Methods
This was a descriptive prospective study conduct-
ed over a period of 17 months extending from August
2004 till January 2006. Patients of all age groups and both
genders with diagnosis of chronic ITP who visited the
haematology out-patient clinic, or underwent splenecto-
my during the study period were included.  Patients with
secondary causes of thrombocytopenia or with concomi-
tant autoimmune hemolytic anemia i.e. Evans syndrome
were excluded.
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The diagnosis of idiopathic thrombocytopenic purpura was
made on isolated thrombocytopenia and on the exclusion of
other causes of thrombocytopenia and that was confirmed
by bone marrow aspirate.
The patients were managed according to guidelines
provided by British Society of Hematology6 which state
that:
* No treatment is required in case where platelet counts
are than 30x109/L or patient has no signs and symptoms of
bleeding unless they are undergoing any surgical procedure
which is likely to induce blood loss.
* When required; first line treatment is given with
steroids (prednisone 1mg/kg/day for 2-4 weeks, tapering off
over several weeks) in case when platelet counts dropped
further or patient had haemorrhagic symptoms. 
* Intravenous immunoglobulin (IVIg) is considered as
first line therapy, however responses are transient.
* Splenectomy as second line agent was indicated in all
patients with chronic ITP who failed to respond to steroids,
or required higher doses of steroids (prednisone more than
10mg/day) to maintain platelets count greater than
30x109/L.   
The following criteria were used to assess the
response to therapy.13-15
Complete response (CR): Achievement of normal
platelet counts i.e. greater than 150x109/L atleast two
months after surgery.
Partial response (PR): Achievement of platelet count
greater than 50x109/L atleast two months after surgery, or
greater than 30x109/L only without continued drug admin-
istration.
No response (NR): Failure to achieve platelet count
above 30x109/L.
Relapse was defined as a drop in the platelet count to
below 150x109/L after CR.
All statistical analysis was computed with SPSS sta-
tistical software (version 13.0.1). Data was presented as
mean or median values; and percentages. The following
variables were studied for their prognostic value on the
achievement of response: young age, sex, disease duration,
initial response to corticosteroids, platelet count at presenta-
tion and after surgery. Differences between responders and
non-responders were evaluated by using the chi-square. A
p-value of less than 0.05 was considered to be statistically
significant.
Results
A total of eighty six patients with chronic ITP were
studied. Of these 31 (36%) were males and 55 (64%) were
females, with a mean age at the time of diagnosis of 25.5
years (range: 2-65 years). At the time of diagnosis, 33
(38.3%) patients were less than 15 years of age, while at the
time of splenectomy 23 (26.7%) patients were found in this
age group. Patient characteristics are summarized in Table 1
First line treatment with steroids was required in 83
patients, while three had platelet counts greater than
30x109/L. Although intravenous immunoglobulin (IVIg)
was considered as first-line treatment but it was not used as
initial treatment modality in our series.  
The response with steroids was complete (CR) in 15
(18.1%) patients, 20 (24.1%) and 48 (57.8%) patients
showed partial (PR) and no response (NR) respectively.
When the response to steroid therapy was correlated with
the patient age, sex and platelet count of less than 20x109/L
at presentation no significant association was noted (p-value
0.53, 0.9, 0.2 respectively) (Table 2).
Out of 48 patients who were refractory to steroids;
45 ultimately required splenectomy, 2 were lost to follow-
up and the remaining one patient was not fit for general
anaesthesia. Of the 35 patients who had initial complete or
partial response to steroids; 29 ultimately underwent
splenectomy due to disease relapse.
Hence a total of 74 (86%) patients with chronic ITP
were subjected to splenectomy. At the time of splenectomy,
48 patients had disease duration of around one year. After
splenectomy, 37 patients (50%) had complete recovery, 10
(13.5%) went into partial remission, and 27 (36.5%) showed
no response. Four (5.4%) of the responders subsequently
relapsed after a median interval of 12 months (2-24 months). 
Sex (male/female) (%)
Mean age at time of diagnosis (years)
Range  
Mean age at time of splenectomy (years)
Range       
Median time between diagnosis and splenectomy 
i.e. disease duration (months)
Range  
Median number of platelets at time of diagnosis
Range                                                                      
Median time of remission Post-splenectomy (months)
Range                                                                         
Median time of relapse post-splenectomy (months)  
Range 
31(36%) / 55 (64%)
25.5 
(2-65 )
27 
(5-60 )
19.1 
(6-660)
9 x109/L
(1-65x109/L)
27.6
(11-127.2) 
12
(2-24)
Table 1. Patient characteristics at the time of diagnosis (n=86) and
splenectomy (n=74).
Table 2. Comparison of the factors which affect initial response to
steroids. 
Responders 
(CR+PR)
(n=35)
Non- respon-
ders 
(n=48)
P-value
Age < 15 years
Male/Female
Platelet count at pres-
entation <20x109/L 
16
13 / 22 
31
17
17/ 31
46
0.53
0.90    
0.2
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To see the significance of various factors which can predict
response of splenectomy, the patients were grouped into
responders (CR+PR) and non-responders. It was observed
that younger age, gender, low platelet count at time of diag-
nosis, time duration from diagnosis to splenectomy did not
significantly influence the splenectomy outcome. 
However, out of 29 patients with previous complete
or partial response to steroids, 25 (86.2%) attained CR or
PR with splenectomy while four (13.8%) patients did not
respond (p=0.003).
Twenty seven patients had platelet counts greater
than 300x109/L on day 14 of surgery. Of these; 25 (92.5%)
were responders to splenectomy- CR (n=23) and PR (n=2)
(p=0.001) (Table 3). 
Only one patient died of gram negative sepsis which
she developed within two months of surgery.
Discussion
The ultimate outcome of chronic ITP is unpre-
dictable.10 
In our series, initial treatment with steroids resulted
in CR in 17% of cases, which is comparable with previous
studies.12-13,16 In contrast to this, considerable higher
response rate with steroids (41% and 47%) was observed in
other studies.17,18
Comparable to previous data16-18, younger age, sex
and platelet count at presentation were not associated with
better response to steroids in our group.
Splenectomy remains the treatment of choice in
chronic ITP showing CR in 50%, the results compared
favorably with those of Chen et al.19 However even higher
response rates had been reported by various studies.1,18, 20
The prognostic factors of successful splenectomy in
ITP have been of much interest for decades. Many studies
failed to demonstrate any such prognostic parameter.11
In the present study, an initial complete or partial
response to corticosteroid was statistically significant in
predicting response with splenectomy. Similar prognostic
correlation has been reported in the past21 and some recent
studies.18 Some studies failed to show a significant associa-
tion.6,10,22
Similarly high platelet counts within two weeks
post-operatively showed a favorable outcome in our series.
There are consistent with other reports.1,23,24
Contrary to previous reports11, we were not able to
identify young age19,23, sex; disease duration and low
platelet count at presentation to be prognostic parameters
for a successful splenectomy. Our results are comparable
with some other study results.10,25
Indium-labelled autologus platelet scanning for detect-
ing principal site of platelet sequestration is the most sensitive
indicator to predict the response of splenectomy. This was not
utilized in our study due to non availability of the test. 
It is worth noting that splenectomy caused no signif-
icant morbidity. In previous reports; the overall mortality of
splenectomy ranged from 0.2-1.5%20, however we experi-
enced only one (0.01%).  
Conclusion
Splenectomy remains an effective and safe treatment
for chronic ITP. No factor has been identified to help in pre-
dicting response of first line treatment. However, prior sta-
ble response with steroids and high post-operative platelet
count, were associated with CR after splenectomy. 
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